• Radiopharm Theranostics completed an FDA end-of-Phase 2 meeting for RAD101, setting the framework for a pivotal brain-metastases imaging program.
• Phase 2b results were previously presented, supporting continued development based on performance versus standard imaging assessments.
• The update shifts focus to Phase 3 readiness work ahead of FDA meeting minutes expected within about 30 days.
• RAD101 holds FDA Fast Track status, strengthening its regulatory positioning for a registrational study.
• Siemens Healthineers will manufacture and distribute RAD101 doses for the planned U.S. Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED1001276171) on October 05, 2026, and is solely responsible for the information contained therein.